Primary tumor

NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer

Retrieved on: 
Tuesday, March 7, 2023
Managed Care, Research, Radiology, Pharmaceutical, Oncology, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, MD, Pancreas, Treatment, Toxic epidermal necrolysis, Toxicity, Patent, Prostate, ICIS, LSAM, Lung, Patient, Neoplasm, Immune system, Primary tumor, Pharmaceutical industry, Medical imaging, Cancer

The patent ( 11,583,499 ) is valid in the US until November 25, 2038, and has corresponding filings globally.

Key Points: 
  • The patent ( 11,583,499 ) is valid in the US until November 25, 2038, and has corresponding filings globally.
  • ICIs are often used in combination with other systemic cancer therapies particularly in the treatment of solid tumors to prime the immune system to increase response.
  • “The Cancer Research Institute estimates more than 5000 clinical trials are underway worldwide with immune checkpoint inhibitors; many are combination trials with other systemic cancer agents in solid tumors.” said Gere DiZerega, MD, NanOlogy Chief Medical Officer.
  • “The goal is to identify which combinations can increase the immune response thereby increasing the overall solid tumor response to treatment.

Adjuvant Opdivo (nivolumab) Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years in CheckMate -274 Trial

Retrieved on: 
Friday, February 17, 2023
Oncology, Health, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, Bristol Myers Squibb, Rated R, Checkmate, American Society of Clinical Oncology, Mount Sinai, Immunotherapy, Confidence interval, Translational research, Icahn School of Medicine at Mount Sinai, NYSE, Primary tumor, Bladder cancer, Patient, HIV disease progression rates, Recurrence, Carcinoma, Lymph, Research, BMY, Risk, Associate, Death, Disease, Progression-free survival, DFS, Society, Clinical Genitourinary Cancer, Cancer, Kidney, ASCO, Pharmaceutical industry, Medical imaging, Nivolumab

Bristol Myers Squibb (NYSE: BMY) today announced three-year follow-up results from the Phase 3 CheckMate -274 trial, demonstrating significant sustained clinical benefits with Opdivo (nivolumab) for the adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced three-year follow-up results from the Phase 3 CheckMate -274 trial, demonstrating significant sustained clinical benefits with Opdivo (nivolumab) for the adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma.
  • “Patients with muscle-invasive urothelial carcinoma face a high chance of recurrence due to micrometastatic disease, especially within the first three years after surgical removal of the bladder or kidney.
  • “We strive to provide hope for patients by offering safe and effective options that may help prevent recurrence and improve long-term outcomes.
  • “The durable follow-up results from CheckMate -274 continue to fuel our excitement toward our ongoing research in earlier stages and its potential to change outcomes for patients.

Ferronova secures A$11 million to advance nanotech image-guided cancer therapy

Retrieved on: 
Sunday, January 22, 2023
Proton, University, Proton therapy, University of Sydney, Primary tumor, Royal Adelaide Hospital, Environment, Cancer, Artesian, Element, Surgeon, South Australian Health and Medical Research Institute, Research, Brain, Indocyanine green, Health, Patient, Lymph, University of South Australia, Pharmaceutical industry, Medical imaging, Renewal

Irish company Renew Pharmaceuticals Limited (Renew) led an A$8 million capital raise, with a further A$3 million secured via an Australian Government Co-operative Research Centers Project (CRC-P) grant.

Key Points: 
  • Irish company Renew Pharmaceuticals Limited (Renew) led an A$8 million capital raise, with a further A$3 million secured via an Australian Government Co-operative Research Centers Project (CRC-P) grant.
  • * Existing Ferronova shareholders, led by Uniseed with Artesian Venture Partners also participated.
  • The latest round of funding for the Adelaide, South Australian headquartered company builds on seed capital and Series A funding of $4.6 million.
  • Improvement in precision imaging, surgery, and therapy are now essential to improving long term outcomes.

Ferronova secures A$11 million to advance nanotech image-guided cancer therapy

Retrieved on: 
Sunday, January 22, 2023
Proton, University, Proton therapy, University of Sydney, Primary tumor, Royal Adelaide Hospital, Environment, Cancer, Artesian, Element, Surgeon, South Australian Health and Medical Research Institute, Research, Brain, Indocyanine green, Health, Patient, Lymph, University of South Australia, Pharmaceutical industry, Medical imaging, Renewal

Irish company Renew Pharmaceuticals Limited (Renew) led an A$8 million capital raise, with a further A$3 million secured via an Australian Government Co-operative Research Centers Project (CRC-P) grant.

Key Points: 
  • Irish company Renew Pharmaceuticals Limited (Renew) led an A$8 million capital raise, with a further A$3 million secured via an Australian Government Co-operative Research Centers Project (CRC-P) grant.
  • * Existing Ferronova shareholders, led by Uniseed with Artesian Venture Partners also participated.
  • The latest round of funding for the Adelaide, South Australian headquartered company builds on seed capital and Series A funding of $4.6 million.
  • Improvement in precision imaging, surgery, and therapy are now essential to improving long term outcomes.

Circulating Tumor Cells (CTC) Global Market Report 2022: Featuring BioFluidica, Fluxion Biosciences, Menarini Silicon Biosystems & More - ResearchAndMarkets.com

Retrieved on: 
Monday, November 21, 2022
Health, Oncology, Lung, Prevalence, Blood, R, Liquid biopsy, Nanotechnology, Bachelor of Engineering, Drug development, Prostate cancer, Patient, Cancer, Research, Primary tumor, COVID-19, Diagnosis, MI, Fortis Healthcare, Metastasis, Breast, Microscopy, CTC, Medical imaging, Growth

The "Circulating Tumor Cells (CTC) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Circulating Tumor Cells (CTC) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global circulating tumor cells (CTC) market size reached US$ 9.54 Billion in 2021.
  • Circulating tumor cells (CTC) are cancer cells that split away from the primary tumor and appear in the circulatory system as singular units or clusters.
  • Circulating Tumor Cells (CTC) Market Trends:
    increasing prevalence of cancer due to genetic disorders, rising alcohol consumption, and rapid lifestyle changes are key factors driving the market growth.

Beyond Cancer™ Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
Convention center, Adult, NTM, Urinary tract infection, Immunotherapy, Death, Survival, Policy, Company, Program, Administration, Security (finance), Radiation, GNO, Forward-looking statement, UNO, Annual general meeting, Pulmonology, Society for Immunotherapy of Cancer, U.S. Securities and Exchange Commission, Time, Nitric oxide, Neoplasm, Wilms' tumor, Patient, COVID-19, Pulmonary hypertension, Ultra, Metastasis, Mouse, ICI, NO, Toxicity, Nontuberculous mycobacteria, Society, Primary tumor, FDA, GLOBE, Technology, Annual report, NASDAQ, Hypoxemia, Safety, Atmosphere of Earth, Boston Convention and Exhibition Center, SITC, Respiratory distress syndrome, Pharmaceutical industry, Vaccine, Medical imaging, Cancer

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced promising new in vivo combination data that support the potential of the company’s novel gaseous nitric oxide (gNO) therapy to treat various types of solid tumors in combination with immune checkpoint inhibitor (ICI) therapies, including anti-PD-1. These data were published in an abstract by the Society for Immunotherapy of Cancer (SITC) and will be presented in a poster presentation today at the 37th Annual SITC Meeting in Boston, MA.

Key Points: 
  • These data were published in an abstract by the Society for Immunotherapy of Cancer (SITC) and will be presented in a poster presentation today at the 37th Annual SITC Meeting in Boston, MA.
  • We believe these promising data provide a strong rationale for the continued advancement of this program in combination with immune checkpoint therapies.
  • Our combination data presented today at the SITC 2022 Annual Meeting show an effect on the primary tumor and, importantly, can treat metastatic disease and not just prevent it.
  • Ultra-high concentration Nitric Oxide (UNO) therapy is a completely new approach to preventing relapse or metastatic disease.

NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update

Retrieved on: 
Wednesday, November 9, 2022
European Investment Bank, GLOBE, NBTXR3, Private Securities Litigation Reform Act, Head, Forward-looking statement, Radiation, Primary tumor, Webcast, Liver disease, Risk, EIB, Board, Society for Immunotherapy of Cancer, COVID-19, US, SEC, Congress, NASDAQ, Annual report, U.S. Securities and Exchange Commission, NANO, SITC, Lung, Company, Cancer, Patient, Society, AMF, Medical imaging, Pharmaceutical industry, Security (finance), Public relations, Immunotherapy, Nanobiotix, Euronext

We are eager to share additional Phase 1 data from Study 1100 at the annual SITC congress.

Key Points: 
  • We are eager to share additional Phase 1 data from Study 1100 at the annual SITC congress.
  • Nanobiotix reported cash and cash equivalents totaling 53.5 million as of September 30, 2022, compared to 83.9 million as of December 31, 2021.
  • During the call, Laurent Levy, chief executive officer, and Bart Van Rhijn, chief financial officer, will briefly review the Companys third quarter results and provide an update on business activities before taking questions from participants.
  • A live webcast of the call may be accessed by visiting the investors section of the companys website at www.nanobiotix.com.

T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial

Retrieved on: 
Thursday, October 20, 2022
SAN, TCR, Trust, Therapy, Neoplasm, Patient, Cancer/testis antigens, Human, MYT, Cancer, Technology, Mouse, Blood, Molecular medicine, Safety, Testicle, GLOBE, Hlas, Clinical trial, MAGE-A1, Berlin, Max, Genetic engineering, Antigen, HLA, Primary tumor, Pharmaceutical industry, Medical imaging, Vaccine

We are excited to bring our first MyT Platform derived product candidate into the clinic, added Thomas M. Soloway, Chief Executive Officer of T-knife.

Key Points: 
  • We are excited to bring our first MyT Platform derived product candidate into the clinic, added Thomas M. Soloway, Chief Executive Officer of T-knife.
  • The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial designed to evaluate the safety and preliminary efficacy of TK-8001 in patients with MAGE-A1 positive solid tumors.
  • The Phase 1 part of the study is focused on the selection of a dose to advance into the Phase 2 part of the study.
  • Once the recommended Phase 2 dose has been identified, TK-8001 will then be evaluated in an expansion part of the trial.

SURGE Therapeutics Raises $26M Series A Financing to Accelerate Development of Intraoperative Immunotherapy to Improve Survival Outcomes Post-Surgery

Retrieved on: 
Monday, October 17, 2022
Research, General Health, Professional Services, Pharmaceutical, Oncology, Hospitals, Health Technology, Surgery, Science, Biotechnology, Medical Supplies, Finance, Health, Boston Scientific, LinkedIn, Therapy, American Association for Cancer Research, Neoplasm, Surgical oncology, Patient, Drug development, Standard of care, Research, Harvard Medical School, Metastasis, Doctor of Science, Cancer, Coronavirus Scientific Advisory Board (Turkey), HHMI, Harvard University, Doctor of Philosophy, Cancer Research Institute, SURGE, American Association, Society, Association, CEO, Khosla Ventures, MIT, Immunotherapy, Safety, Recurrence, Survival, Bristol Myers Squibb, Surgeon, View, Primary tumor, Pharmaceutical industry, Medical imaging, MD

The funds will be used to accelerate development of the SURGE intraoperative immunotherapy approach, expand the team, and initiate clinical trials for its injectable biodegradable hydrogel.

Key Points: 
  • The funds will be used to accelerate development of the SURGE intraoperative immunotherapy approach, expand the team, and initiate clinical trials for its injectable biodegradable hydrogel.
  • To this end, SURGE is developing immunotherapies that can be injected directly into the site of tumor resection (intraoperative immunotherapy), to improve cancer patient survival and, ultimately, the standard of care.
  • SURGE Therapeutics (The Intraoperative Immunotherapy Company) seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed.
  • SURGE, SURGE Therapeutics, SURGERx, and The Interoperative Immunotherapy Company are trademarks of SURGE Therapeutics, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221017005003/en/

Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Retrieved on: 
Wednesday, September 21, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Mall of America, RCC, Metastasis, HNSCC, Cervical cancer, COVID-19, Twitter, Risk, LRR, NSCLC, Nivolumab, Hepatocellular carcinoma, EIB, U.S. Securities and Exchange Commission, LinkedIn, Company, Private Securities Litigation Reform Act, Immunotherapy, Neoplasm, Forward-looking statement, Patient, Primary tumor, Cancer, NANO, Lung, Melanoma, Metadata, Annual report, TNBC, Nanoparticle, Radiation, Head, Liver, NASDAQ, Wilms' tumor, Renal cell carcinoma, AMF, Squamous cell carcinoma, SEC, Neck, NBTXR3, Pharmaceutical industry, Medical imaging, Nanobiotix, Euronext

The combined dose escalation and dose expansion parts of Study 1100 are expected to enroll up to 141 patients.

Key Points: 
  • The combined dose escalation and dose expansion parts of Study 1100 are expected to enroll up to 141 patients.
  • Study participants received a one-time intratumoral injection of NBTXR3 prior to their first radiotherapy session.
  • Nanobiotix aims to deliver an industry-leading head and neck cancer treatment franchise powered by NBTXR3, and to replicate that approach across other solid tumor indications.
  • Pursuant to this strategy, the Company has amended the ongoing expansion phase of Study 1100 to further strengthen the rationale behind a registrational protocol evaluating NBTXR3 plus anti-PD-1 for patients with R/M HNSCC that is resistant to prior immunotherapy.